Clinical Trials Logo

Hereditary Angioedema clinical trials

View clinical trials related to Hereditary Angioedema.

Filter by:

NCT ID: NCT06262399 Not yet recruiting - Clinical trials for Hereditary Angioedema

Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002

Start date: April 2024
Phase:
Study type: Observational

This is a follow-up study of subjects who received NTLA-2002 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.

NCT ID: NCT06007677 Enrolling by invitation - Clinical trials for Hereditary Angioedema

A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema

Start date: September 26, 2023
Phase: Phase 2
Study type: Interventional

The goal of this trial is to enable the collection of information about long-term safety and clinical activity of STAR-0215 in participants with hereditary angioedema (HAE). Participants will receive repeat doses of STAR-0215 for up to 5 years.

NCT ID: NCT05695248 Recruiting - Clinical trials for Hereditary Angioedema

A Study of STAR-0215 in Participants With Hereditary Angioedema

Start date: February 21, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical trial is to test the drug STAR-0215 in participants with hereditary angioedema (HAE). One group of participants will get 1 dose of STAR-0215, and two other groups will get 2 doses of STAR-0215. Researchers will study the effects of STAR-0215 in participants with HAE as this is the first time that the drug has been given to participants with HAE.

NCT ID: NCT05691361 Recruiting - Clinical trials for Hereditary Angioedema

Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients

Start date: December 14, 2022
Phase: Phase 1
Study type: Interventional

The first-in-human Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-324 in healthy volunteers (HV) and in patients with Hereditary Angioedema (HAE).

NCT ID: NCT05511922 Recruiting - Clinical trials for Hereditary Angioedema

PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

Start date: October 24, 2022
Phase: Phase 3
Study type: Interventional

This is a multicenter pharmacokinetic (PK) subtrial to investigate the PK profile of KVD900 in adolescent patients 12 to 17 years of age with Hereditary Angioedema (HAE) type I or II.

NCT ID: NCT05505916 Recruiting - Clinical trials for Hereditary Angioedema

An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Start date: October 24, 2022
Phase: Phase 3
Study type: Interventional

This is an open-label, multicenter extension trial to evaluate the long-term safety of KVD900 in patients who are 12 years or older with HAE type I or II.

NCT ID: NCT05477160 Completed - Clinical trials for Hereditary Angioedema

A Study of STAR-0215 in Healthy Adult Participants

Start date: July 27, 2022
Phase: Phase 1
Study type: Interventional

This is a first-in-human, single-center, randomized, double-blind, placebo-controlled, single ascending dose study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single subcutaneous (SC) or intravenous (IV) administration of STAR-0215 in healthy adult participants.

NCT ID: NCT05453968 Active, not recruiting - Pediatric Clinical Trials

Berotralstat Treatment in Children With Hereditary Angioedema

APeX-P
Start date: October 25, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetics (PK) and safety of berotralstat to determine the appropriate weight-based dose for pediatric participants 2 to < 12 years old for prophylactic treatment to prevent attacks of hereditary angioedema (HAE).

NCT ID: NCT05396105 Recruiting - Clinical trials for Hereditary Angioedema

Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

RAPIDe-2
Start date: December 28, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

This study evaluates the safety and efficacy of long-term on-demand treatment with orally administered deucrictibant for acute hereditary angioedema (HAE) attacks, including laryngeal attacks, in patients with HAE due to C1-esterase inhibitor (C1-INH) deficiency (type I/II). The study will enroll patients from Study PHA022121-C201 (NCT04618211) who elect to participate in this extension study and meet the eligibility requirements.

NCT ID: NCT05392114 Recruiting - Clinical trials for Hereditary Angioedema

A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

Start date: July 13, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the long-term safety and efficacy of donidalorsen in people with HAE and the effects of donidalorsen on the number of HAE attacks and their impact on quality of life (QoL).